TG Therapeutics Inc (NASDAQ: TGTX) on Monday, plunged -17.99% from the previous trading day, before settling in for the closing price of $35.02. Within the past 52 weeks, TGTX’s price has moved between $16.65 and $46.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 443.80%. With a float of $142.98 million, this company’s outstanding shares have now reached $158.75 million.
The firm has a total of 338 workers. Let’s measure their productivity. In terms of profitability, gross margin is 87.43%, operating margin of 15.48%, and the pretax margin is 10.8%.
TG Therapeutics Inc (TGTX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of TG Therapeutics Inc is 9.93%, while institutional ownership is 62.54%. The most recent insider transaction that took place on Jun 13 ’25, was worth 369,400. In this transaction Director of this company sold 10,000 shares at a rate of $36.94, taking the stock ownership to the 228,816 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Director proposed sale 10,000 for $36.93, making the entire transaction worth $369,348.
TG Therapeutics Inc (TGTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 443.80% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
TG Therapeutics Inc (TGTX) is currently performing well based on its current performance indicators. A quick ratio of 3.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.37, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 1.75 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Analysing the last 5-days average volume posted by the [TG Therapeutics Inc, TGTX], we can find that recorded value of 3.82 million was better than the volume posted last year of 2.47 million. As of the previous 9 days, the stock’s Stochastic %D was 11.74%.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 2.42%, which indicates a significant decrease from 3.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.58 in the past 14 days, which was lower than the 1.87 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.63, while its 200-day Moving Average is $34.10.
